News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
中生製藥(01177.HK)維特柯妥拜單抗胃癌III期臨床試驗完成首例患者入組
中國生物製藥(01177.HK)公布，集團全資附屬公司禮新醫藥自主研發的國家1類創新藥維特柯妥拜單抗(CLDN18.2 ADC)正在開展聯合PD-1單抗一線治療CLDN18.2陽性局部晚期或轉移性胃及胃食管交界部腺癌(GC/GEJ)的Ⅲ期註冊臨床試驗(LM302-03-201)，已順利完成首例患者入組。該研究為LM-302開展的第二項Ⅲ期臨床試驗，也是全球首...
Reset
Send
The window will close in 5 seconds
中生製藥(01177.HK)維特柯妥拜單抗胃癌III期臨床試驗完成首例患者入組
Close
Recommend
17
Positive
28
Negative
12
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

中國生物製藥(01177.HK)  -0.130 (-2.185%)    Short selling $90.75M; Ratio 22.538%   公布，集團全資附屬公司禮新醫藥自主研發的國家1類創新藥維特柯妥拜單抗(CLDN18.2 ADC)正在開展聯合PD-1單抗一線治療CLDN18.2陽性局部晚期或轉移性胃及胃食管交界部腺癌(GC/GEJ)的Ⅲ期註冊臨床試驗(LM302-03-201)，已順利完成首例患者入組。

該研究為LM-302開展的第二項Ⅲ期臨床試驗，也是全球首個CLDN18.2 ADC藥物採用無化療方案用於胃癌一線治療的Ⅲ期臨床試驗。(sl/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-21 16:25.)

AASTOCKS新聞

Switch to Auto-Translated Version
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.